<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 獲取免費報告) 在三月份的空頭頭寸顯著下降。截至 3 月 13 日，空頭頭寸總計為 8,091,418 股，較 2 月 26 日的 10,152,747 股下降了 20.3%。目前，該公司的 8.4% 股份被做空。根據平均每日交易量 12,856,933 股，當前的空頭頭寸比率為 0.6 天。</p>
<h2>華爾街分析師預測增長</h2>
<p>DAWN 最近成為多份分析師報告的主題。JonesTrading 將 Day One Biopharmaceuticals 的股票評級從 “買入” 下調至 “持有”，並在 3 月 6 日的研究報告中將其目標價從 20.00 美元上調至 21.50 美元。TD Cowen 在 3 月 6 日的研究報告中將 Day One Biopharmaceuticals 的股票評級從 “買入” 下調至 “持有”。Oppenheimer 在 3 月 6 日的研究報告中重申了對 Day One Biopharmaceuticals 的 “市場表現” 評級。Zacks Research 在 2 月 25 日的研究報告中將 Day One Biopharmaceuticals 的股票評級從 “強力買入” 下調至 “持有”。最後，摩根大通在 3 月 11 日的研究報告中重申了 “中性” 評級，並將目標價設定為 21.50 美元（從 27.00 美元下調）。一位股票研究分析師給予該股票 “買入” 評級，八位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，平均目標價為 23.29 美元。</p>
<p><strong>閲讀我們關於 Day One Biopharmaceuticals 的最新報告</strong></p>
<h2>Day One Biopharmaceuticals 的內部買賣</h2>
<p>在其他 Day One Biopharmaceuticals 的新聞中，首席財務官 Charles N. York II 於 2 月 17 日出售了 6,065 股公司的股票。該股票以平均價格 11.60 美元出售，總交易額為 70,354.00 美元。出售完成後，首席財務官持有 312,025 股公司股票，估值約為 3,619,490 美元。此次交易使其持股減少了 1.91%。該交易已在向 SEC 提交的文件中披露，文件可通過 SEC 網站訪問。此外，內部人士 Michael Vasconcelles 於 2 月 17 日出售了 2,728 股公司的股票。該股票以平均價格 11.60 美元出售，總價值為 31,644.80 美元。出售完成後，該內部人士持有 4,397 股公司的股票，估值約為 51,005.20 美元。此次交易使其持股減少了 38.29%。該銷售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士共出售了 36,461 股公司股票，價值 422,948 美元。當前 6.20% 的股票由公司內部人士持有。</p>
<h2>對 Day One Biopharmaceuticals 的對沖基金看法</h2>
<p>機構投資者最近買入和賣出了該股票的股份。AIGH Capital Management LLC 在第三季度購買了價值約 10,719,000 美元的 Day One Biopharmaceuticals 新頭寸。AlphaQuest LLC 在第三季度將其在 Day One Biopharmaceuticals 的持股增加了 1,065.6%。AlphaQuest LLC 目前擁有 185,006 股公司股票，價值 1,304,000 美元，此前在上個季度購買了 169,134 股。施羅德投資管理集團在第二季度購買了價值約 1,171,000 美元的 Day One Biopharmaceuticals 新股份。Mak Capital One LLC 在第三季度購買了價值約 10,212,000 美元的 Day One Biopharmaceuticals 新股份。最後，Geode Capital Management LLC 在第二季度將其在 Day One Biopharmaceuticals 的股份增加了 11.2%。Geode Capital Management LLC 目前擁有 1,712,429 股公司股票，價值 11,132,000 美元，此前在上個季度購買了 171,964 股。87.95% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Day One Biopharmaceuticals 股票表現</h2>
<p>DAWN 的股票在週一開盤價為 21.41 美元。該公司的 50 日移動平均線為 14.62 美元，200 日移動平均線為 10.55 美元。Day One Biopharmaceuticals 的 12 個月低點為 5.64 美元，12 個月高點為 21.46 美元。該公司的市值為 22.1 億美元，市盈率為-20.79，貝塔值為-1.25。</p>
<p>Day One Biopharmaceuticals (NASDAQ:DAWN - 獲取免費報告) 最近於 2 月 24 日發佈了季度財報。該公司報告季度每股收益為（0.21 美元），低於市場共識預期的（0.17 美元）0.04 美元。該季度的營業收入為 5372 萬美元，而市場共識預期為 4981 萬美元。Day One Biopharmaceuticals 的股本回報率為負的 23.43%，淨利潤率為負的 67.85%。股票研究分析師預測，Day One Biopharmaceuticals 在當前年度的每股收益將為-0.72。</p>
<h2>Day One Biopharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN 是一家臨牀階段的生物製藥公司，專注於針對腫瘤的靶向治療的發現和開發。該公司採用精準醫療的方法，利用生物標誌物驅動的策略來識別最有可能對其研究化合物產生反應的患者羣體。通過集中關注經過良好驗證的癌症分子驅動因素，Day One 力求提供具有重要臨牀益處的首創或最佳治療方案。</p>
<p>該公司的產品管線包括多個處於不同開發階段的小分子候選藥物。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Day One Biopharmaceuticals</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Day One Biopharmaceuticals 嗎？</h2>
<p>在考慮投資 Day One Biopharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Day One Biopharmaceuticals 並不在名單上。</p>
<p>雖然 Day One Biopharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DAWN

<p>Day One Biopharmaceuticals, Inc.（納斯達克代碼：DAWN）在三月份的空頭頭寸下降了 20.3%，總計 8,091,418 股。該公司約有 8.4% 的股份被做空，覆蓋天數比率為 0.6 天。分析師已下調了該股票的評級，平均目標價格為 23.29 美元。內部交易活動包括首席財務官 Charles N. York II 和內部人士 Michael Vasconcelles 的股票出售。機構投資者持有 87.95% 的股份，開盤價為 21.41 美元，市值為 22.1 億美元</p>

<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) saw a significant decline in short interest in March. As of March 13th, there was short interest totaling 8,091,418 shares, a decline of 20.3% from the February 26th total of 10,152,747 shares. Currently, 8.4% of the shares of the company are short sold. Based on an average daily volume of 12,856,933 shares, the short-interest ratio is presently 0.6 days.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 獲取免費報告) 在三月份的空頭頭寸顯著下降。截至 3 月 13 日，空頭頭寸總計為 8,091,418 股，較 2 月 26 日的 10,152,747 股下降了 20.3%。目前，該公司的 8.4% 股份被做空。根據平均每日交易量 12,856,933 股，當前的空頭頭寸比率為 0.6 天。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>DAWN has been the topic of a number of recent analyst reports. JonesTrading cut shares of Day One Biopharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating and raised their target price for the stock from $20.00 to $21.50 in a research note on Friday, March 6th. TD Cowen lowered shares of Day One Biopharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, March 6th. Oppenheimer reissued a &#34;market perform&#34; rating on shares of Day One Biopharmaceuticals in a research note on Friday, March 6th. Zacks Research downgraded shares of Day One Biopharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, February 25th. Finally, JPMorgan Chase &amp; Co. restated a &#34;neutral&#34; rating and set a $21.50 target price (down from $27.00) on shares of Day One Biopharmaceuticals in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and an average target price of $23.29.</p>
<div class="lb-trans"><p>DAWN 最近成為多份分析師報告的主題。JonesTrading 將 Day One Biopharmaceuticals 的股票評級從 “買入” 下調至 “持有”，並在 3 月 6 日的研究報告中將其目標價從 20.00 美元上調至 21.50 美元。TD Cowen 在 3 月 6 日的研究報告中將 Day One Biopharmaceuticals 的股票評級從 “買入” 下調至 “持有”。Oppenheimer 在 3 月 6 日的研究報告中重申了對 Day One Biopharmaceuticals 的 “市場表現” 評級。Zacks Research 在 2 月 25 日的研究報告中將 Day One Biopharmaceuticals 的股票評級從 “強力買入” 下調至 “持有”。最後，摩根大通在 3 月 11 日的研究報告中重申了 “中性” 評級，並將目標價設定為 21.50 美元（從 27.00 美元下調）。一位股票研究分析師給予該股票 “買入” 評級，八位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，平均目標價為 23.29 美元。</p>
</div><p><strong>Read Our Latest Report on Day One Biopharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Day One Biopharmaceuticals 的最新報告</strong></p>
</div><h2>Insider Buying and Selling at Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 的內部買賣</h2>
</div><p>In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 6,065 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $70,354.00. Following the completion of the sale, the chief financial officer owned 312,025 shares of the company's stock, valued at approximately $3,619,490. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Michael Vasconcelles sold 2,728 shares of the company's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $31,644.80. Following the completion of the sale, the insider owned 4,397 shares of the company's stock, valued at approximately $51,005.20. The trade was a 38.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,461 shares of company stock valued at $422,948 in the last ninety days. 6.20% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Day One Biopharmaceuticals 的新聞中，首席財務官 Charles N. York II 於 2 月 17 日出售了 6,065 股公司的股票。該股票以平均價格 11.60 美元出售，總交易額為 70,354.00 美元。出售完成後，首席財務官持有 312,025 股公司股票，估值約為 3,619,490 美元。此次交易使其持股減少了 1.91%。該交易已在向 SEC 提交的文件中披露，文件可通過 SEC 網站訪問。此外，內部人士 Michael Vasconcelles 於 2 月 17 日出售了 2,728 股公司的股票。該股票以平均價格 11.60 美元出售，總價值為 31,644.80 美元。出售完成後，該內部人士持有 4,397 股公司的股票，估值約為 51,005.20 美元。此次交易使其持股減少了 38.29%。該銷售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士共出售了 36,461 股公司股票，價值 422,948 美元。當前 6.20% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>對 Day One Biopharmaceuticals 的對沖基金看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the stock. AIGH Capital Management LLC bought a new position in shares of Day One Biopharmaceuticals during the 3rd quarter valued at about $10,719,000. AlphaQuest LLC increased its holdings in shares of Day One Biopharmaceuticals by 1,065.6% in the third quarter. AlphaQuest LLC now owns 185,006 shares of the company's stock worth $1,304,000 after purchasing an additional 169,134 shares during the last quarter. Schroder Investment Management Group purchased a new stake in shares of Day One Biopharmaceuticals in the second quarter worth about $1,171,000. Mak Capital One LLC purchased a new stake in shares of Day One Biopharmaceuticals in the third quarter worth about $10,212,000. Finally, Geode Capital Management LLC boosted its stake in Day One Biopharmaceuticals by 11.2% during the second quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company's stock valued at $11,132,000 after buying an additional 171,964 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近買入和賣出了該股票的股份。AIGH Capital Management LLC 在第三季度購買了價值約 10,719,000 美元的 Day One Biopharmaceuticals 新頭寸。AlphaQuest LLC 在第三季度將其在 Day One Biopharmaceuticals 的持股增加了 1,065.6%。AlphaQuest LLC 目前擁有 185,006 股公司股票，價值 1,304,000 美元，此前在上個季度購買了 169,134 股。施羅德投資管理集團在第二季度購買了價值約 1,171,000 美元的 Day One Biopharmaceuticals 新股份。Mak Capital One LLC 在第三季度購買了價值約 10,212,000 美元的 Day One Biopharmaceuticals 新股份。最後，Geode Capital Management LLC 在第二季度將其在 Day One Biopharmaceuticals 的股份增加了 11.2%。Geode Capital Management LLC 目前擁有 1,712,429 股公司股票，價值 11,132,000 美元，此前在上個季度購買了 171,964 股。87.95% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Day One Biopharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 股票表現</h2>
</div><p>Shares of DAWN opened at $21.41 on Monday. The business's 50 day moving average is $14.62 and its 200 day moving average is $10.55. Day One Biopharmaceuticals has a 12-month low of $5.64 and a 12-month high of $21.46. The company has a market capitalization of $2.21 billion, a PE ratio of -20.79 and a beta of -1.25.</p>
<div class="lb-trans"><p>DAWN 的股票在週一開盤價為 21.41 美元。該公司的 50 日移動平均線為 14.62 美元，200 日移動平均線為 10.55 美元。Day One Biopharmaceuticals 的 12 個月低點為 5.64 美元，12 個月高點為 21.46 美元。該公司的市值為 22.1 億美元，市盈率為-20.79，貝塔值為-1.25。</p>
</div><p>Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The business had revenue of $53.72 million during the quarter, compared to the consensus estimate of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%. Equities research analysts predict that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals (NASDAQ:DAWN - 獲取免費報告) 最近於 2 月 24 日發佈了季度財報。該公司報告季度每股收益為（0.21 美元），低於市場共識預期的（0.17 美元）0.04 美元。該季度的營業收入為 5372 萬美元，而市場共識預期為 4981 萬美元。Day One Biopharmaceuticals 的股本回報率為負的 23.43%，淨利潤率為負的 67.85%。股票研究分析師預測，Day One Biopharmaceuticals 在當前年度的每股收益將為-0.72。</p>
</div><h2>Day One Biopharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN 是一家臨牀階段的生物製藥公司，專注於針對腫瘤的靶向治療的發現和開發。該公司採用精準醫療的方法，利用生物標誌物驅動的策略來識別最有可能對其研究化合物產生反應的患者羣體。通過集中關注經過良好驗證的癌症分子驅動因素，Day One 力求提供具有重要臨牀益處的首創或最佳治療方案。</p>
</div><p>The company's pipeline includes several small-molecule candidates in various stages of development.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個處於不同開發階段的小分子候選藥物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Day One Biopharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Day One Biopharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Day One Biopharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Day One Biopharmaceuticals 嗎？</h2>
</div><p>Before you consider Day One Biopharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Day One Biopharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Day One Biopharmaceuticals 並不在名單上。</p>
</div><p>While Day One Biopharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Day One Biopharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Day One Biopharmaceuticals, Inc.（NASDAQ:DAWN）在三月份的空頭頭寸減少了 20.3%